Prelude Therapeutics Inc. (PRLD)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Krishna Vaddi
Employees:
120
200 POWDER MILL ROAD, WILMINGTON, DE 19803
(302) 547-3768

Prelude Therapeutics Incorporated focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Data derived from most recent annual or quarterly report
Market Cap 134.754 Million Shares Outstanding47.955 Million Avg 30-day Volume 111.031 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.58
Price to Revenue0.0 Debt to Equity0.0 EBITDA-113.712 Million
Price to Book Value0.9657 Operating Margin0.0 Enterprise Value-1.907 Million
Current Ratio17.13 EPS Growth0.093 Quick Ratio16.787
1 Yr BETA 1.2046 52-week High/Low 8.67 / 2.66 Profit Margin0.0
Operating Cash Flow Growth-3.0073 Free Cash Flow to Firm (FCFF) TTM -99.403 Million Free Cash Flow to Equity (FCFE) TTM-90.832 Million
Altman Z-Score5.9051
Earnings Report2023-11-14
View SEC Filings from PRLD instead.

View recent insider trading info

Prelude Therapeutics Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding PRLD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PRLD

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-07-06 by HUANG JANE
  • 4: filed on 2023-06-21 by DIER MARDI
  • 4: filed on 2023-06-21 by BONITA DAVID P
  • 4: filed on 2023-06-21 by BABLER MARTIN
  • 4: filed on 2023-05-26 by VADDI KRISHNA
  • 4: filed on 2023-05-25 by LIM BRYANT DAVID
  • 4: filed on 2023-05-25 by VADDI KRISHNA
  • 4: filed on 2023-05-24 by ORBIMED ADVISORS LLC
  • 4: filed on 2023-05-24 by BONITA DAVID P
  • 4: filed on 2023-05-24 by BAKER JULIAN

    • Events (8k)

  • 8-K: filed on 2023-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-06-01:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-17:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-15:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-14:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-23:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HUANG JANE PRESIDENT, CMO

    • Officer
    		 30,353 2023-07-04 3

    BAKER BROS. ADVISORS LP

    667, L.P.

    BAKER JULIAN

    BAKER FELIX

    BAKER BROS. ADVISORS (GP) LLC

    BAKER BROTHERS LIFE SCIENCES LP

    • Director
    • 10% Owner
    		 0 2023-06-16 2

    FRIEDMAN PAUL A

    • Director
    		 0 2023-06-16 1

    BABLER MARTIN

    • Director
    		 0 2023-06-16 1

    BONITA DAVID P

    • Director
    • 10% Owner
    		 0 2023-06-16 2

    DIER MARDI

    • Director
    		 0 2023-06-16 1

    SANDOR VICTOR

    • Director
    		 0 2023-06-16 1

    LIM BRYANT DAVID CHIEF LEGAL OFFICER, CORP SEC.

    • Officer
    		 2,400 2023-05-24 3

    VADDI KRISHNA CEO

    • Officer
    • Director
    		 3,781,520 2023-05-24 4

    CHARDONNET LAURENT CHIEF FINANCIAL OFFICER

    • Officer
    		 42,165 2023-05-23 4

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    ORBIMED CAPITAL LLC

    • Director
    • 10% Owner
    		 10,646,056 2023-05-22 1

    SCHERLE PEGGY CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2023-02-07 1

    COMBS ANDREW EVP, HEAD OF CHEMISTRY

    • Officer
    		 0 2023-02-07 1

    MOROSINI DEBORAH EVP, CHIEF OF CLINICAL AFFAIRS

    • Officer
    		 90,000 2022-02-15 0

    MAURO DAVID J CHIEF MEDICAL OFFICER

    • Officer
    		 137,610 2021-10-05 0

    PIERCE CHRISTOPHER EVP AND CHIEF OF BUSINESS OPER

    • Officer
    		 211,546 2021-09-02 0

    PIPER BRIAN CHIEF FINANCIAL OFFICER

    • Officer
    		 264,329 2021-08-25 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    • Director
    • 10% Owner
    		 206,912 2020-09-24 1

    NEU KELVIN

    • Director
    		 0 2020-09-24 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    PRELUDE THERAPEUTICS INC PRLD 2023-09-25 13:45:04 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-25 13:15:04 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-25 12:45:06 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 22:15:03 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 21:45:04 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 21:15:04 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 20:45:04 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 20:15:04 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 19:45:03 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 19:15:04 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 18:45:03 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 18:15:04 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 17:45:04 UTC 0.0 0.0 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 17:15:04 UTC 0.0 0.0 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 16:45:03 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 16:15:04 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 15:45:04 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 15:15:04 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 14:45:03 UTC 4.2606 1.0594 200000
    PRELUDE THERAPEUTICS INC PRLD 2023-09-22 14:15:04 UTC 4.2606 1.0594 200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments